BMS-741672

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H33F3N6O3S
Molecular Weight	542.617
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)N(C)[C@@H]1CC[C@@H]([C@@H](C1)NS(C)(=O)=O)N2CC[C@H](NC3=C4C=C(C=CC4=NC=N3)C(F)(F)F)C2=O

InChI

InChIKey=PJTGSIKANITYOO-RCOXNQKVSA-N

InChI=1S/C24H33F3N6O3S/c1-14(2)32(3)16-6-8-21(20(12-16)31-37(4,35)36)33-10-9-19(23(33)34)30-22-17-11-15(24(25,26)27)5-7-18(17)28-13-29-22/h5,7,11,13-14,16,19-21,31H,6,8-10,12H2,1-4H3,(H,28,29,30)/t16-,19+,20-,21+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C24H33F3N6O3S
Molecular Weight	542.617
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:20:47 GMT 2025` Edited by `admin` on `Mon Mar 31 23:20:47 GMT 2025`
Record UNII	3UAA36FHF1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BMS-741672

Common Name

English

BMS 741672

Preferred Name

English

BMS 741672 [WHO-DD]

Common Name

English

BMS741672

Common Name

English

N-(5-(ISOPROPYL(METHYL)AMINO)-2-(2-OXO-3-((6-(TRIFLUOROMETHYL)QUINAZOLIN-4-YL)AMINO)PYRROLIDIN-1-YL)CYCLOHEXYL)METHANESULFONAMIDE

Systematic Name

English

Code System Code Type Description

CAS

1386991-77-0

Created by admin on Mon Mar 31 23:20:47 GMT 2025 , Edited by admin on Mon Mar 31 23:20:47 GMT 2025

PRIMARY

FDA UNII

3UAA36FHF1

Created by admin on Mon Mar 31 23:20:47 GMT 2025 , Edited by admin on Mon Mar 31 23:20:47 GMT 2025

PRIMARY

PUBCHEM

154572822

Created by admin on Mon Mar 31 23:20:47 GMT 2025 , Edited by admin on Mon Mar 31 23:20:47 GMT 2025

PRIMARY

Related Record Type Details


					5XA76PCG9F

C-C CHEMOKINE RECEPTOR TYPE 2

TARGET -> INHIBITOR

Qualification:

IC50

Amount:

Related Record Type Details


					3UAA36FHF1

BMS-741672

ACTIVE MOIETY

Comments:

Drugs: BMS 741672 (Primary); Indication: Type 2 diabetes mellitus; Focus: Therapeutic Use; Sponsor: Bristol-Myers Squibb; Most Recent Events: 29 Jun 2010 Actual patient number (58) added as reported by ClinicalTrials.gov., 29 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov., 11 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.